Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.

AI/ML

Biotechnology

Health Care

Software

Oncoustics AI

Oncoustics AI's headquarters in Toronto, Canada

Beth Rogozinski

James Wang

Shahid Rashid

Ahmed E.

Engineering and Development

Clinical and Data Operations

Oncoustics AI

Org chart

Teams

Engineering and Development

Clinical and Data Operations

Offices

Similar companies